Palisade Bio(US:PALI) Globenewswire·2026-03-02 14:00Core Viewpoint - Palisade Bio, Inc. is advancing its clinical-stage biopharmaceutical development of a next-generation oral PDE4 inhibitor prodrug, PALI-2108, aimed at treating inflammatory and fibrotic diseases, with upcoming investor presentations scheduled for March 2026 [1][2][3]. Group 1: Company Overview - Palisade Bio is focused on developing oral PDE4 inhibitor prodrugs that enhance pharmacology, tolerability, and convenience for patients suffering from inflammatory and fibrotic diseases [3]. - The company's lead program, PALI-2108, is designed for targeted delivery in the ileum and colon, achieving a 100% clinical response in a recent Phase 1b trial for ulcerative colitis (UC) without serious adverse events [4]. Group 2: Clinical Development - Palisade Bio is progressing towards a Phase 2 clinical study in UC, which will evaluate clinical remission, response, and pharmacodynamic biomarkers over a 12-week period, including an extension phase for maintenance of remission [5]. - The company is also conducting early studies in fibrostenotic Crohn's disease to further assess the safety and therapeutic potential of PALI-2108 across various inflammatory bowel disease indications [5]. Group 3: Investor Engagement - Palisade Bio will participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026, and the Leerink Partners 2026 Global Healthcare Conference from March 8-11, 2026, providing opportunities for investors to engage with management [1][2].